Cambridge, United States
Arbor Biotechnologies, founded in 2016, is at the forefront of the Biopharma, Biotechnology, and Life Sciences industries. Based in the United States, this next-generation gene editing company aims to tackle genetic diseases with its slogan, "Genetic medicines for genetic diseases."
The company stands out with its extensive toolbox of proprietary genomic editors, enabling it to select the optimal solutions for each disease, effectively working backward from disease pathology. This innovative approach positions Arbor Bio as a pioneer in potentially curative genomic medicine development.
In its recent financing milestone, Arbor Biotechnologies secured a Late VC investment dated 01 October 2025, with Samsung Ventures as a key investor. This investment not only reinforces confidence in the company's strategic vision but also underlines its potential for significant impact in the realm of genetic therapies.
